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Indicators of intrauterine development, such 
as birth weight and small for gestational age 
(SGA), are predictors of infant survival and 
the prevalence of chronic diseases in adult-
hood (Barker 2002; Risnes et al. 2011). Diet 
during pregnancy is a well-recognized deter-
minant of fetal growth (Godfrey and Barker 
2000). A decade ago it was shown that acryl-
amide is formed during heating of food at 
high temperatures, and that it is found in a 
variety of foods (Dybing et al. 2005; Tareke 
et al. 2000, 2002). Acrylamide has been in 
industrial use since the 1950s and is also pres-
ent in cigarette smoke (Bergmark 1997; Shipp 
et al. 2006). Acrylamide has shown neurotoxic 
effects in humans with occupational expo-
sures (Hagmar et al. 2001) and is classified as 
a probable human carcinogen (International 
Agency for Research on Cancer 1994). Its 
metabolite glycidamide is assumed to be the 
genotoxic agent of acrylamide (Rice 2005). 
Acrylamide is known to induce developmental 
and reproductive toxicity in animals including 
effects on fetal growth (Manson et al. 2005).
In humans, fetal exposure to acrylamide 
through the diet may start in utero, because 
acrylamide has been found to cross the placenta 
barrier in vitro (Annola et al. 2008; Sörgel et al. 
2002) as well as in vivo (Schettgen et al. 2004; 
von Stedingk et al. 2011). Recently, we showed 
that higher acrylamide exposure among non-
smoking pregnant women was associated with 
reduced fetal growth based on birth weight 
and SGA (Pedersen et al. 2012). That study 
included 1,101 women from five different 
European countries, and the exposure assess-
ment was based on acrylamide hemoglobin 
(Hb) adduct levels measured in cord blood, as 
well as food scores created from acrylamide-
rich food intakes obtained from food frequency 
questionnaires (FFQ).
Dietary acrylamide exposure estimated 
from FFQ data used in the The Norwegian 
Mother and Child Cohort Study (MoBa) has 
previously been validated using urine metabo-
lites as biomarker of recent intakes (Brantsaeter 
et al. 2008b). N-terminal Hb adducts reflect 
longer time window for exposure (approxi-
mately 120 days circulation time for erythro-
cytes) compared with urine metabolites (just 
a few days), and have been used for biomoni-
toring acrylamide exposure in many studies 
(e.g., Törnqvist et al. 2006). The validity of 
Hb adducts as a marker of acrylamide expo-
sure from food has been demonstrated in ani-
mal studies as well as in human intervention 
studies (Abramsson-Zetterberg et al. 2008; 
Naruszewicz et al. 2009). In other studies 
comparing FFQ-based acrylamide intake esti-
mates with measured acrylamide–Hb adduct 
concentrations low to moderate correlations 
were observed (Bjellaas et al. 2007; Kütting 
et al. 2008; Tran et al. 2010; Wilson et al. 
2009a, 2009b; Wirfält et al. 2008).
In this study we explored the hypothesis 
that dietary acrylamide exposure during pre-
natal life might impair fetal growth, resulting 
in increased SGA and reduced birth weight 
in a large population-based cohort study in 
Norway: MoBa. We also aimed to identify 
population characteristics associated with 
higher intakes of acrylamide. The FFQ-based 
estimates of acrylamide intake were further 
evaluated by comparisons with measurements 
of acrylamide– and glycidamide–Hb adducts 
in a subset of the study participants.
Methods
Population and study design. MoBa is 
a prospective population-based pregnancy 
cohort study conducted by the Norwegian 
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Background: Acrylamide has shown developmental and reproductive toxicity in animals, as well as 
neurotoxic effects in humans with occupational exposures. Because it is widespread in food and can 
pass through the human placenta, concerns have been raised about potential developmental effects 
of dietary exposures in humans.
oBjectives: We assessed associations of prenatal exposure to dietary acrylamide with small for ges-
tational age (SGA) and birth weight.
Methods: This study included 50,651 women in the Norwegian Mother and Child Cohort Study 
(MoBa). Acrylamide exposure assessment was based on intake estimates obtained from a food fre-
quency questionnaire (FFQ), which were compared with hemoglobin (Hb) adduct measurements 
reflecting acrylamide exposure in a subset of samples (n = 79). Data on infant birth weight and ges-
tational age were obtained from the Medical Birth Registry of Norway. Multivariable regression was 
used to estimate associations between prenatal acrylamide and birth outcomes.
results: Acrylamide intake during pregnancy was negatively associated with fetal growth. When 
women in the highest quartile of acrylamide intake were compared with women in the lowest 
quartile, the multivariable-adjusted odds ratio (OR) for SGA was 1.11 (95% CI: 1.02, 1.21) and the 
coefficient for birth weight was –25.7 g (95% CI: –35.9, –15.4). Results were similar after excluding 
mothers who smoked during pregnancy. Maternal acrylamide– and glycidamide–Hb adduct levels 
were correlated with estimated dietary acrylamide intakes (Spearman correlations = 0.24; 95% CI: 
0.02, 0.44; and 0.48; 95% CI: 0.29, 0.63, respectively).
conclusions: Lowering dietary acrylamide intake during pregnancy may improve fetal growth.
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Institute of Public Health (Magnus et al. 
2006). Participants were recruited from all 
over Norway during 1999–2008, and 38.5% 
of invited women consented to participate. 
The cohort now includes 108,000 children, 
90,700 mothers, and 71,500 fathers. Blood 
samples were obtained from both parents dur-
ing pregnancy and from mothers and chil-
dren (umbilical cord) at birth. Follow-up 
is conducted by questionnaires at regular 
intervals and by linkage to national health 
registries. Several substudies are conducting 
additional collections of data and biologi-
cal materials. The present study is based on 
version 5 of the quality-assurance data files 
released for research in June 2010 (unpub-
lished data). Informed consent was provided 
by each MoBa participant upon recruitment. 
The study was approved by the Regional 
Committee of Medical Research Ethics for 
South-Eastern Norway.
Women were eligible for the present 
analysis if they were recorded in the Medical 
Birth Registry of Norway (MBRN) and had 
singleton births, and they completed ques-
tionnaires 1 and 3 (in weeks 17 and 30 of 
pregnancy, respectively), baseline MoBa ques-
tionnaires covering information on sociode-
mographic characteristics, exposure to tobacco 
smoke during pregnancy, and general health; 
questionnaire 2 (during weeks 23–24 of preg-
nancy), which covered dietary information; 
and questionnaire 4 (when the child was 
6 months of age), which collected information 
on maternal health at time of delivery, includ-
ing maternal weight gain during pregnancy 
(n = 62,124) (Norwegian Institute of Public 
Health 2007). We then excluded women if 
they participated in MoBa with multiple preg-
nancies (n = 6,604), if gestational age at the 
child’s birth was < 28 weeks or > 42 weeks 
(n = 385), if data were missing on birth weight 
(n = 22) or maternal smoking during preg-
nancy (n = 817), or if the mother’s estimated 
energy intake was < 4,500 kJ or > 20,000 kJ 
(n = 796). In addition, we excluded women 
with missing (n = 2,386) or improbable values 
for weight gain during pregnancy (< –30 kg or 
> 50 kg) (n = 463), leaving a study sample of 
50,651 women. Because smoking is negatively 
associated with birth weight and is a significant 
source of acrylamide exposure, we performed 
additional analyses stratified on self-reported 
smoking during pregnancy (46,420 nonsmok-
ers and 4,231 smokers).
Dietary information. The MoBa FFQ 
(MoBa 2002) was used for calculation of 
acrylamide intake. This FFQ is a semiquan-
titative questionnaire designed to provide 
information on dietary habits and dietary sup-
plement intakes during the first 4–5 months 
of pregnancy (Meltzer et al. 2008). It has been 
thoroughly validated with regard to foods and 
nutrients (Brantsaeter et al. 2008a). For each 
of the 255 food and beverage items, the fre-
quency of consumption was reported by select-
ing one of 8–10 possible frequencies, ranging 
from never to several times monthly, weekly, 
or daily. Energy intake was calculated from 
the FFQ using FoodCalc (Lauritsen 2005) 
and the Norwegian Food Composition table 
(Rimestad et al. 2005).
To calculate acrylamide intake, we pre-
pared a database containing values of acryl-
amide concentration reported from analyses 
of Norwegian food items (Norwegian Food 
Safety Authority 2002, 2006; Scientific 
Committee of the Norwegian Food Safety 
Authority 2002) and the Swedish National 
Food Administration (Livsmedelsverket 2002). 
For foods not analyzed in Norway or Sweden, 
we collected data from the European Union 
database (Institute for Reference Materials and 
Measurements 2005). For food items with 
multiple analyses of acrylamide concentration, 
the median concentration was used. Examples 
of the values assigned for each food group have 
previously been published (Brantsaeter et al. 
2008b). To identify food group predictors of 
higher acrylamide intake, the 255 food items 
in the FFQ were grouped into 19 food groups 
based on nutrient profiles, culinary usage, or 
known acrylamide levels. For example, cereals 
and potatoes were classified into four separate 
food groups: fried potatoes; crisp bread; bread, 
which included dark and white bread; and 
other, including breakfast cereal, rice, couscous, 
pasta, and pizza.
Hb adduct measurements. Hb adducts 
from acrylamide and glycidamide were mea-
sured in blood samples collected from 81 
mothers who gave birth between 2007 and 
2009 at Oslo University Hospital at Ullevål 
or Akershus University Hospital and enrolled 
in the BraMiljö and BraMat MoBa subco-
horts (Gützkow et al. 2012; Stølevik et al. 
2011). A common protocol for the European 
Commission–financed integrated proj-
ect NewGeneris (Newborns and Genotoxic 
Exposure Risks) was followed (Merlo et al. 
2009). In brief, maternal blood samples were 
analyzed for Hb adducts from acrylamide 
and glycidamide by application of the adduct 
FIRE procedure and analysis with liquid chro-
matography–mass spectrometry (Shimadzu 
prominence/AB Sciex 3200 qtrap; Shimadzu 
Corporation, Kyoto, Japan), as described 
by von Stedingk et al. (2010). The method 
performance of the adduct FIRE procedure 
for acrylamide and glycidamide–Hb adduct 
measurements has previously been described 
(von Stedingk et al. 2010, 2011). We excluded 
Hb adduct data from two women who 
reported smoking during pregnancy, leaving 
data from 79 women for comparisons with 
estimated dietary intakes.
Birth outcomes and other variables. Birth 
weight was measured by the midwife who 
attended the birth and reported to MBRN 
(Irgens 2000). Gestational age was calculated 
on the basis of first-trimester ultrasound in 
98.2% of MoBa participants. In the event of 
a missing ultrasound measure, gestational age 
was calculated from last menstrual period. 
For births during 34–42 weeks of gesta-
tion, SGA was defined as birth weight below 
the 10th percentile of births among MoBa 
participants according to the week of gesta-
tional age at birth and parity (primiparous 
or multiparous). For children born during 
weeks 28–33 we used MBRN data published 
in 2000 to determine the 10th percentile of 
birth weight according to gestational age and 
parity (Skjaerven et al. 2000).
Parity was classified based on data from 
both MoBa and MBRN and categorized as 
primiparous or multiparous. Data on mater-
nal education attainment (≤ 12, 13–16, and 
≥ 17 years), age, and smoking were collected 
from questionnaires. Smoking during preg-
nancy was categorized as nonsmoker, occa-
sional smoker, or daily smoker. Participants 
with unknown/missing values for education or 
father’s smoking were grouped in a “missing” 
category. Prepregnancy weight and height were 
self-reported at week 17 of pregnancy and used 
to calculate prepregnancy body mass index 
(BMI), which was categorized as underweight 
(< 18.5 kg/m2), normal weight (18.5–24.9 kg/
m2), overweight (25.0–29.9 kg/m2), or obese 
(≥ 30.0 kg/m2). Sex of the child and weight of 
the mother at the time of delivery (kilograms) 
were collected from questionnaire 4. Maternal 
weight gain during pregnancy (kilograms) was 
calculated from weight reported at the start 
of pregnancy and at the time of delivery, as 
registered at the birth clinic on the women’s 
health card.
Statistical analyses. Spearman correlations 
were used to examine the relationship between 
dietary acrylamide intakes and measured 
maternal Hb adduct concentrations of acryl-
amide and glycidamide. Dietary acrylamide 
intakes were divided by total energy to derive 
energy-adjusted intake estimates (nanograms 
per kilocalorie per day) that are expressed as 
means ± SDs. Maternal and newborn charac-
teristics are summarized according to quartiles 
of energy-adjusted acrylamide intakes and dif-
ferences across quartiles were tested using chi-
square or Kruskal–Wallis tests.
We used multivariable linear regression 
models to identify food groups that signifi-
cantly predicted dietary acrylamide intakes 
and population characteristics associated with 
acrylamide intake.
We used multivariable logistic regression 
models to estimate associations between ener-
gy-adjusted dietary acrylamide intakes during 
pregnancy (categorized according to quartiles or 
modeled as a continuous variable) and SGA at 
birth, and linear regression models to estimate 
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associations with birth weight. Potential con-
founders were assessed from a wide array of 
variables available in MoBa and were retained 
in all final models if they resulted in a change 
in estimate > 10% for either SGA or birth 
weight. Covariates in final models were gesta-
tional age, parity, sex of the child, age of the 
mother, maternal prepregnancy BMI, maternal 
weight gain during pregnancy, and smoking 
during pregnancy. Other potential covariates 
(type of delivery, parental education, income, 
father’s weight and height, marital status, and 
exposure to passive smoking) did not meet our 
criteria for confounding of associations with 
either SGA or birth weight, nor did maternal 
intakes of food groups such as snacks, sweets 
(including cakes and chocolate), dairy prod-
ucts, alcohol, or coffee, or intakes of supple-
ments reflecting a healthy diet, such as fiber, 
folate, or folate supplements (data not shown).
We tested potential interactions between 
acrylamide intakes and active or passive 
smoking during pregnancy by including inter-
action terms in the regression models, but 
no significant interactions were observed (p 
for interaction > 0.10, data not shown). We 
confirmed that results were comparable after 
excluding preterm births (< 37 weeks gesta-
tion, n = 2,279), low birth weight children 
(< 2,500 g, n = 1,309), and women with miss-
ing information for education (n = 1,022) 
or partner’s smoking during pregnancy 
(n = 2,240) (data not shown). Results were 
similar when analyses were repeated using esti-
mated acrylamide exposure relative to body 
weight (micrograms per kilogram body weight 
per day), and when the residual approach was 
used to adjust for energy intake or body weight 
(data not shown). In addition, our results were 
comparable after increasing or decreasing the 
levels of exposure in a randomly selected 20% 
subset as a sensitivity analysis, and when we 
used error-in-variables regression (Carroll et al. 
1995) assuming only 80% reliability in the 
estimated ranking of acrylamide intake (data 
not shown). Data were analyzed using STATA 
10.1 (StataCorp, College Station, TX, USA).
Results
Acrylamide intake estimates and measured 
Hb adducts among nonsmokers. Acrylamide– 
and glycidamide–Hb adducts were measured 
in 79 nonsmokers as markers of the internal 
dose of acrylamide. Mean maternal Hb adduct 
levels were 31 pmol/g Hb (range, 9.9–72, 
n = 79) for acrylamide and 23 pmol/g Hb 
(range, 8.8–44, n = 79) for glycidamide. A 
strong correlation between acrylamide– and 
glycidamide–Hb adduct levels (Spearman 
correlation = 0.62, p < 0.001, n = 79) was 
observed. Correlations between maternal 
acrylamide– or glycidamide–Hb adduct levels 
and energy-adjusted dietary acrylamide intakes 
estimated from the FFQ were 0.24 (95% CI: 
0.02, 0.44) and 0.48 (95% CI: 0.29, 0.63) 
respectively (Figure 1).
Acrylamide intake during pregnancy and 
fetal growth indicators. Overall, the mean ± SD 
acrylamide intake among the 50,651 pregnant 
women was 27.1 ± 13.4 µg/day, 0.4 ± 0.2 µg/kg 
body weight/day, or 11.7 ± 4.6 ng/kcal/day. 
The food groups that most strongly predicted 
acrylamide intakes among pregnant women 
in the Norwegian MoBa study were snacks, 
which included potato chips, nuts, and pop-
corn; fried potatoes; and crisp bread [coeffi-
cients ± SEs were 0.17 ± 0.001, 0.15 ± 0.001, 
and 0.13 ± 0.001 respectively, vs. coeffi-
cients ± SEs ranging from –0.026 ± 0.0007 to 
0.009 ± 0.0001 for other food groups (data not 
shown)].
After multivariable adjustment, increas-
ing age, multiparity, lower educational level, 
maternal smoking, and paternal smoking 
during pregnancy were associated with sig-
nificantly higher acrylamide intakes during 
pregnancy (Table 1).
Birth weight and the frequency of SGA 
differed significantly by quartiles of energy-
adjusted acrylamide intake during pregnancy 
(Table 2). The frequency of SGA was higher 
and the mean ± SD of birth weight was lower 
among women in the fourth quartile of acryl-
amide intake compared with women in the 
first quartile (11.0% and 3,591 ± 542 g vs. 
9.6% and 3,612 ± 534 g respectively, p-values 
for all comparisons < 0.05).
Energy-adjusted acrylamide intake dur-
ing pregnancy, modeled continuously or in 
quartiles, was significantly associated with 
SGA, with an adjusted odds ratio (OR) 
among all women of 1.11 (95% CI: 1.02, 
1.21) for the highest quartile of acrylamide 
intake compared with the lowest quartile 
(Table 3). Associations were similar when 
stratified on maternal smoking (ORs for the 
highest versus lowest quartiles of 1.13; 95% 
CI: 1.03, 1.23 among nonsmokers; and 1.14; 
Figure 1. Relationships for acrylamide– and glycidamide–Hb adducts versus FFQ-based acrylamide esti-
mated intake among nonsmoking pregnant women (n = 79). 
Table 1. Population characteristics and dietary acrylamide intake during pregnancy.
Characteristics of acrylamide intake n (%) β (95% CI) p-Value
Mother’s age (years) 30.08 ± 4.51 0.026 (0.02, 0.04) < 0.001
Parity
Nulliparous 26,320 (52.0) Reference
Multiparous 24,331 (48.0) 0.170 (0.08, 0.26) < 0.001
Prepregnancy BMI (kg/m2)
18.5–25 33,405 (66.0) Reference
< 18.5 1,437 (2.8) 0.115 (–0.13, 0.36) 0.358
25–30 11,144 (22.0) 0.063 (–0.04, 0.16) 0.216
> 30 4,665 (9.2) –0.082 (–0.22, 0.06) 0.263
Maternal education (years)
≤ 12 15,243 (30.1) Reference
13–16 21,847 (43.1) –0.205 (–0.30, –0.10) < 0.001
≥ 17 12,539 (24.8) –0.535 (–0.65, –0.42) < 0.001
Missing 1,022 (2.0) –0.513 (–0.81, –0.22) 0.001
Maternal smoking during pregnancy
Nonsmokers 46,420 (91.7) Reference
Occasional smoking 2,261 (4.5) 1.181 (0.98, 1.38) < 0.001
Daily smoking 1,970 (3.9) 1.486 (1.27, 1.71) < 0.001
Father smoking during pregnancy
Nonsmokers 38,325 (75.7) Reference
Occasional smoking 2,656 (5.2) 0.190 (0.01, 0.37) 0.041
Daily smoking 7,430 (14.7) 0.158 (0.03, 0.28) 0.011
Missing 2,240 (4.4) 0.104 (–0.10, 0.30) 0.310
Values are mean ± SD or n (%). Results are from multivariate linear regression model of energy-adjusted acrylamide 
intake (ng/kcal/day), adjusted simultaneously for all variables shown in the table.
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95% CI: 0.90, 1.45 among smokers), though 
estimates for the smaller group of smokers 
were not significant.
Acrylamide intake was negatively associ-
ated with birth weight, with a multivariable-
adjusted coefficient of –25.7 g (95% CI: –35.9, 
–15.4) for birth weight for all women in the 
fourth quartile compared with women in the 
first quartile, and similar results after exclusion 
of smokers (Table 4). Stronger associations 
were observed among the smokers compared 
with the overall population [multivariable-
adjusted coefficient –50.0 g (95% CI: –86.5, 
–16.6)] for the fourth quartile compared with 
the first quartile of acrylamide intake].
Discussion
In this study, higher maternal dietary acryl-
amide intakes during pregnancy were associ-
ated with evidence of impaired fetal growth 
based on an increase in SGA and a reduction in 
birth weight; similar results were obtained after 
excluding women who smoked during preg-
nancy. Dietary acrylamide intakes estimated 
from the MoBa FFQ were correlated with mea-
sured Hb adduct levels in a subset of mater-
nal samples. The three food groups that most 
strongly predicted high intakes of acrylamide 
were snacks, which included potato chips, nuts, 
and popcorn; fried potatoes; and crisp bread. 
Maternal age, parity, education, and exposure 
to tobacco smoke also predicted the intake of 
dietary acrylamide during pregnancy.
Our results are in agreement with findings 
from a recent study of associations between 
fetal growth indicators and prenatal expo-
sure to acrylamide in mother–child cohorts 
from five countries in Europe (Pedersen 
et al. 2012). Significant negative associations 
between maternal acrylamide exposure and 
birth weight among nonsmoking women were 
reported. Acrylamide exposure was estimated 
based on Hb adduct measurements in 1,101 
cord blood samples, and by applying a food 
score approach based on the intake of acryl-
amide-rich foods collected by FFQs (n = 801).
Negative effects of prenatal exposure to 
acrylamide on fetal growth have been observed 
in animal studies with doses of a few milli-
grams per kilogram per day, as reviewed by 
Manson et al. (2005), though mechanisms 
are unknown. Perfusion studies have shown 
that acrylamide can cross the placental barrier 
in humans (Annola et al. 2008; Sörgel et al. 
2002), and measurements of Hb adducts 
from acrylamide in maternal and cord blood 
samples have demonstrated that acrylamide is 
circulated in the body of the fetus (Schettgen 
et al. 2004; von Stedingk et al. 2011). Both 
acrylamide and its metabolite glycidamide are 
reactive electrophiles that have the potential to 
react with nucleophilic sites in biomacromol-
ecules, which could affect cellular processes of 
importance for growth. In addition to acryl-
amide, other Maillard products with poten-
tial toxic effects also are formed during heat 
processing of foods (Chaudhry et al. 2006), 
and observed associations with acrylamide 
exposure may therefore reflect combined 
Table 2. Maternal and newborn characteristics in all women and according to quartiles of energy-adjusted dietary acrylamide intake during pregnancy.
Characteristic
All women 
(n = 50,651) Quartile 1a Quartile 2a Quartile 3a Quartile 4a p-Valueb
Range of acrylamide intake (g/day) < 8.5 8.5–11.1 11.1–14.3 > 14.3
Maternal weight gain (kg) 14.9 ± 6.2 14.9 ± 6.0 14.9 ± 5.9 15.0 ± 5.9 14.9 ± 6.2 0.525
Gestational age (weeks) 39.5 ± 1.7 39.5 ± 1.9 39.5 ± 1.7 39.5 ± 1.7 39.5 ± 1.7 0.676
Birth weight (g) 3600.6 ± 539.0 3612.2 ± 533.9 3602.1 ± 538.8 3597.0 ± 541.0 3591.0 ± 541.9 0.014
SGA 5,188 (10.2) 1,216 (9.6) 1,270 (10.0) 1,311 (10.3) 1,391 (11.0) 0.003
Sex (male) 25,906 (51.1) 6,490 (51.2) 6,393 (50.5) 6,466 (51.1) 6,557(51.8) 0.224
Values are mean ± SD or n (%).
aRange of acrylamide intake in ng/kcal/day. bChi-square or Kruskal–Wallis tests. 
Table 3. Associations between dietary acrylamide intakes (ng/kcal/day) during pregnancy and SGA.
Acrylamide intake (ng/kcal/day)
Crude Adjusteda
OR (95% CI) p-Value OR (95% CI) p-Value
All (n = 50,651)
Quartile 1 (< 8.5) Reference Reference
Quartile 2 (8.5–11.1) 1.05 (0.97, 1.14) 0.254 1.05 (0.96, 1.14) 0.255
Quartile 3 (11.1–14.3) 1.09 (1.00, 1.18) 0.046 1.08 (0.99, 1.18) 0.061
Quartile 4 (> 14.3) 1.16 (1.07, 1.26) < 0.001 1.11 (1.02, 1.21) 0.014
Acrylamide intake, 1-SD increase 1.05 (1.03, 1.08) < 0.001 1.03 (1.00, 1.06) 0.029
Nonsmokers, (n = 46,420)
Quartile 1 (< 8.4) Reference Reference
Quartile 2 (8.43–11.0) 1.07 (0.98, 1.17) 0.132 1.08 (0.99, 1.18) 0.092
Quartile 3 (11.0–14.1) 1.07 (0.98, 1.17) 0.132 1.09 (1.00, 1.19) 0.059
Quartile 4 (> 14.1) 1.12 (1.02, 1.22) 0.014 1.13 (1.03, 1.23) 0.008
Acrylamide intake, 1-SD increase 1.03 (1.00, 1.06) 0.056 1.03 (1.00, 1.06) 0.041
Smokers, (n = 4,231)
Quartile 1 (< 9.5) Reference Reference
Quartile 2 (9.5–12.5) 1.12 (0.89, 1.41) 0.344 1.05 (0.83, 1.34) 0.655
Quartile 3 (12.5–16.0) 1.13 (0.90, 1.43) 0.288 1.06 (0.84, 1.35) 0.618
Quartile 4 (> 16.0) 1.23 (0.98, 1.54) 0.079 1.14 (0.90, 1.45) 0.263
Acrylamide intake, 1-SD increase 1.01 (1.00, 1.03) 0.081 1.01 (0.99, 1.02) 0.364
aResults from logistic regression model adjusted for gestational age, parity, sex of the child, age of the mother, maternal 
BMI categorical, maternal gestational weight gain (kg), and smoking during pregnancy.




β (95% CI) p-Value β (95% CI) p-Value
All (n = 50,651)
Quartile 1 (< 8.5) Reference Reference
Quartile 2 (8.50–11.1) –10.1 (–23.35, 3.20) 0.137 –13.0 (–23.19, –2.81) 0.012
Quartile 3 (11.1–14.3) –15.2 (–28.43, –1.88) 0.025 –20.8 (–31.05, –10.65) < 0.001
Quartile 4 (> 14.3) –21.2 (–34.44, –7.89) 0.002 –25.7 (–35.89, –15.44) < 0.001
Acrylamide intake, 1-SD increase –9.2 (–13.87, –4.49) < 0.001 –9.9 (–13.50, -6.27) < 0.001
Nonsmokers (n = 46,420)
Quartile 1 (< 8.4) Reference Reference
Quartile 2 (8.4–11.0) –11.0 (–24.82, 2.83) 0.119 –15.9 (–26.17, –4.94) 0.004
Quartile 3 (11.0–14.1) –9.7 (–23.50, 4.15) 0.170 –19.8 (–30.55, –9.31) < 0.001
Quartile 4 (> 14.1) –14.4 (–28.23, –0.58) 0.041 –25.1 (–35.97, –14.73) < 0.001
Acrylamide intake, 1-SD increase –5.8 (–10.86, –0.92) 0.020 –9.6 (–13.48, –5.84) < 0.001
Smokers (n = 4,231)
Quartile 1 (< 9.5) Reference Reference
Quartile 2 (9.5–12.5) –37.3 (–84.07, 9.53) 0.119 –19.1 (–55.17, 17.04) 0.294
Quartile 3 (12.5–16.0) –45.9 (–92.66, 0.94) 0.055 –31.2 (–67.40, 5.03) 0.092
Quartile 4 (> 16.0) –41.7 (–88.51, 5.11) 0.081 –50.0 (–86.45, –13.62) 0.007
Acrylamide intake, 1-SD increase –12.3 (–26.96, 2.31) 0.099 –12.7 (–24.12, –1.31) 0.030
aResults from linear regression model adjusted for gestational age, parity, sex of the child, age of the mother, maternal 
BMI categorical, maternal gestational weight gain (kg), and smoking during pregnancy.
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exposures to multiple compounds. El-Sayyad 
et al. (2011) reported that pregnant mice fed 
a diet containing 30% fried potato chips gave 
birth to offspring with reduced birth weight, 
and that the reduction in birth weight was 
more pronounced than expected in response 
to acrylamide alone, suggesting a combined 
effect with other compounds. 
Diet is recognized as the primary source 
of acrylamide exposure among nonsmokers 
and non-occupationally exposed popula-
tions, because acrylamide is formed during 
cooking at high temperatures (e.g., frying, 
grilling, or roasting), particularly of carbo-
hydrate-rich foods that contain the amino 
acid asparagine and reducing sugars (Dybing 
et al. 2005). The average acrylamide intake 
among pregnant women in our study popula-
tion was 0.41 µg/kg body weight/day, which 
is close to previously reported intakes for a 
subsample of women from MoBa (0.52 and 
0.44 µg/kg body weight/day based on the 
FFQ and a 4-day food diary, respectively) 
(Brantsaeter et al. 2008b), and to the median 
daily intake estimated in a group of nonpreg-
nant Norwegian women 16–79 years of age 
(0.42 µg/kg body weight/day) (Dybing and 
Sanner 2003). Additionally, an FAO/WHO 
(Food and Agriculture Organization of the 
United Nations/World Health Organization) 
evaluation based on national survey data from 
17 countries concluded that typical acryl-
amide intakes range from 0.3 to 0.8 µg/kg 
body weight/day [JECFA (Joint FAO/WHO 
Expert Committee on Food Additives) 2005].
Smoking was associated with higher dietary 
acrylamide intake in our study population. 
Although the interaction between acrylam-
ide intake and smoking was not statistically 
significant, the association between acrylam-
ide intakes during pregnancy and birth weight 
was stronger among smokers compared with 
nonsmokers. In contrast, the association with 
SGA was comparable among smokers and non-
smokers. Although tobacco smoke is the main 
source of exposure to acrylamide among smok-
ers (Bergmark 1997), the added dietary burden 
among these women may be of concern. 
The observed correlation between FFQ 
data and acrylamide–Hb adduct levels 
(Spearman correlation coefficient = 0.24) is 
in agreement with results reported by other 
investigators, whereas the correlation with 
glycidamide–Hb adducts (0.48) is higher 
than previously reported (Kütting et al. 2008; 
Tran et al. 2010; Wilson et al. 2009a, 2009b; 
Wirfält et al. 2008). Consistent with our find-
ings, two other studies reported a higher cor-
relation coefficient between estimated food 
intake and glycidamide– versus acrylam-
ide–Hb adducts. Tran et al. (2010) reported 
coefficients of 0.21 and 0.16 for glycidamide– 
and acrylamide–Hb adducts, respectively, and 
Wilson et al. (2009b) reported correlation 
coefficients of 0.31 and 0.26, respectively. 
However, individual variation in the capac-
ity to metabolize acrylamide to glycidamide 
would be expected to result in a weaker cor-
relation between dietary acrylamide intakes 
and glycidamide–Hb adducts compared with 
acrylamide–Hb adducts (Duale et al 2009; 
Vikström et al. 2012).
The correlations between acrylamide 
intake estimates based on mid-pregnancy 
FFQs and Hb adduct levels in blood samples 
collected at delivery support the use of the 
FFQ for exposure estimation. In other studies 
in the general population, high within-person 
correlations of Hb adducts over time have 
been reported, suggesting that a single mea-
surement may be a good indicator of aver-
age long-term intake (Vikström et al. 2012; 
Wilson et al. 2009b). The modest correlation 
between estimated dietary intake of acrylam-
ide and Hb adducts indicates the uncertainty 
of these calculations and remains a limitation 
of this study. However, our results were com-
parable when we increased or decreased expo-
sures by 20% in a randomly selected 20% 
subset, and when we used error-in-variables 
regression assuming only 80% reliability in 
the estimated ranking of acrylamide intake.
Acrylamide formation in food is affected 
by several parameters, such as cooking meth-
ods and doneness, that were not assessed 
by the FFQ (Wirfält et al. 2008).  Another 
potential explanation for the moderate corre-
lations between estimated dietary intakes and 
Hb adducts is that factors other than habit-
ual diet may influence the biomarker. This 
includes exceptionally high intakes of acrylam-
ide compared with the average diet, short time 
before the sampling of blood (Vikström et al. 
2012), as well as cigarette smoking, which is 
highly associated with acrylamide–Hb adduct 
levels (Bergmark 1997; von Stedingk et al. 
2011). Thus the FFQ-based estimate may 
have advantages over the biomarker because it 
is less likely to be affected by cigarette smok-
ing. It is well established that both active and 
passive smoking are associated with a reduc-
tion in birth weight and increased risk of SGA 
through a range of potential mechanisms that 
may be independent of acrylamide (Andres 
and Day 2000). Thus using biomarkers that 
do not differentiate between exposure from 
smoking and exposure from dietary sources 
could erroneously lead to the interpretation of 
an effect of acrylamide intake from food that 
in fact could be related to smoking habits.
Selection bias, another potential concern, 
has been extensively explored in MoBa by 
Nilsen et al. (2009). On the basis of com-
parisons with registry data for all births in 
Norway, the authors concluded that although 
the prevalence of some characteristics among 
MoBa participants may show modest differ-
ences from the population as a whole (e.g., 
underrepresentation of women < 25 years, 
those living alone, or smokers), selection bias is 
unlikely to meaningfully influence exposure–
outcome associations involving factors such as 
dietary supplements and smoking.
Our finding that prenatal exposure 
to dietary acrylamide was associated with 
decreased birth weight and increased SGA has 
implications for public health at both early 
and later stages of life (Barker 2002; Godfrey 
and Barker 2000). The associations found in 
this study are relatively modest. However, the 
estimated 25-g reduction in birth weight dis-
tribution (given the mean of 3,600 g) and the 
increase in the risk of SGA were statistically 
significant in our study population of preg-
nant women without abnormally high expo-
sures. Additionally, our results support other 
experimental and epidemiological evidence 
that acrylamide-rich food is associated with 
a reduction in birth weight at exposure lev-
els relevant for the general public (El-Sayyad 
et al. 2011; Pedersen et al. 2012).
Conclusions
In this large population-based cohort study, 
higher prenatal exposure to dietary acryla-
mide was positively associated with SGA and 
negatively associated with birth weight, also 
after excluding smokers during pregnancy. The 
results suggest that prenatal exposure to dietary 
acrylamide may impair fetal growth. Reducing 
dietary acrylamide intake among pregnant 
women might be beneficial for fetal growth.
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